SA IL-33

SA IL-33 is a recombinant fusion protein consisting of serum albumin (SA) fused to interleukin-33 (IL-33). Developed by researchers at the University of Chicago and Imperial College London, this molecule is designed to overcome the short half-life and poor secondary lymphoid organ penetration of native IL-33. By fusing IL-33 to albumin, the protein exhibits enhanced lymph node retention and a prolonged systemic half-life. In preclinical murine models of multiple sclerosis (experimental autoimmune encephalomyelitis, EAE), SA IL-33 has demonstrated the ability to suppress pathogenic Th17 T cells and expand protective ST2+ regulatory T cells (Tregs) and Th2 cells, leading to reduced disease scores and improved weight gain.

Other names

albumin interleukin 33 fusion proteinserum albumin fused IL-33